New Weight-Loss pill ZT006 enters Mid-Stage trial
Disease control
Ongoing
This Phase 2 study tests whether ZT006, a daily or weekly tablet, helps overweight and obese adults lose weight when combined with diet and exercise. About 184 participants will receive either ZT006 or a placebo for 28 weeks, with some continuing for an extra 12 weeks. The main g…
Phase: PHASE2 • Sponsor: Beijing QL Biopharmaceutical Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC